Theravance Biopharma
TBPH
TBPH
90 hedge funds and large institutions have $1.16B invested in Theravance Biopharma in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
90
Holders Change
+6
Holders Change %
+7.14%
% of All Funds
2.07%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
14
Increased
33
Reduced
26
Closed
7
Calls
$2.66M
Puts
$383K
Net Calls
+$2.28M
Net Calls Change
+$3.22M
Top Buyers
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$9.7M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$6.82M |
| 3 |
Goldman Sachs
New York
|
+$6.61M |
| 4 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$3.68M |
| 5 |
Jane Street
New York
|
+$3.43M |
Top Sellers
| 1 |
First Manhattan
New York
|
-$19.7M |
| 2 |
BlackRock
New York
|
-$3.9M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.38M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$846K |
| 5 |
FAM
Foundation Asset Management
White Plains,
New York
|
-$800K |
